Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Announcing new Tapestri Platform updates including lowered input threshold and expanded heme-onc menu. Learn More

Characterize Cell and Gene Therapies Better

Develop safe and efficacious solutions with single-cell analysis.

Why Single Cell for Cell and Gene Therapies?

The development of next-generation cell and gene therapies holds enormous promise for providing curative solutions to a host of genetic diseases. Yet, these therapies are inherently complex and difficult to characterize. The key to the continued success of cell and gene therapies is deepening our understanding of the variation that exists in therapeutic agents and their effects early in discovery.

With Tapestri, you can simultaneously measure multiple genotypic and phenotypic parameters in the same cells, achieving a more comprehensive characterization of your ex-vivo cell therapeutics. With rich analyses serving as a foundation, you can more robustly identify critical quality attributes and accelerate your path to commercialization.

For in vivo gene therapies, Tapestri offers comprehensive single-cell analyses of your model systems, providing valuable insights about the delivery, efficacy, and safety of your therapeutic.

Illustration of ex vivo and in vivo cell and gene therapies.

Ex vivo and in vivo cell and gene therapiesEx vivo cell therapies (left) involves collecting cells from the patient or a donor. The cells may then be genetically modified before they are expanded and infused into the patient. In vivo gene therapies (right) are administered directly to the patient using a vector such as adeno-associated virus (AAV) or lipid nanoparticles.

Measure Multiple Genotypic Attributes in a Single Assay

Many ex vivo cell therapies are genetically modified to induce a therapeutic effect. Yet, these genetic alterations are not consistent across cells — some cells may contain the desired change, while others do not. Whether you are using viral integration of gene editing to alter DNA, Tapestri measures these modulations in thousands of individual cells per sample.

Similarly, Tapestri enables deeper analysis of in vivo gene therapies — such as cell-to-cell variability in the delivery of your vector within your target cells. With richer preclinical data, you can build a robust foundation for the clinical phases of your project.

Our multi-omics assays measure cell-surface markers as an additional layer of information so that you can track immunophenotype along with genotype in each cell.

Illustration of measuring viral modifications and gene editing.

Measuring Viral Integration

For virally-transduced cells, Tapestri can simultaneously measure the transduction efficiency and vector copy number (VCN) at single-cell resolution. Unlike conventional PCR assays, no limiting dilution, standard curve, or cell culture are necessary — shortening your workflow from multiple weeks to days.

Measuring Gene Editing

For therapies modified by CRISPR or other gene-editing tools, Tapestri can concomitantly measure on- and off-target editing in each cell. Additionally, multiplex editing, zygosity, and translocations can be assessed. In contrast to traditional bulk NGS analysis, Tapestri delivers data from individual cells so you can understand cell-to-cell variability in your product.

Robust Characterization of Cell and Gene Therapies with Single-Cell Analysis

Watch our video on Tapestri for Cell and Gene Therapies.

Partnering with Mission Bio

We are your strategic partner for the advancement of your cell and gene therapy pipeline.

Our Pharma Assay Development team will help develop your custom assay — from experimental design and sample processing to data analysis and interpretation. We offer services internally or in partnership with qualified CROs and are invested in bringing more accurate characterization to your early discovery efforts and beyond. We are committed to helping you bring safe, efficacious, and successful therapies to patients faster.

Three icons including a light bulb and a data chart, a correlation graph, and a physician

Learn More about Our Pharma Assay Development

“For the first time ever, we have created a transduction assay that delivers results in days, not months. And the results are incredibly reliable.”

Azadeh Golipour, PhD., AVROBIO


Partnered with Leading Institutions



Bluebird Bio

CRISPR Therapeutics

CSL Behring

Graphite Bio

Homology Medicines

Products and Services

The Tapestri Platform

Tapestri product image with an instrument, reagent kit and analysis software displaying a fish plot
The Tapestri Platform
The first and only multi-omics platform developed to simultaneously measure genotype and immunophenotype at the single-cell level.
Pharma Assay Development
Mission Bio offers single-cell assay services using the Tapestri Platform to support your therapeutic pipeline — from experimental design to analysis and data interpretation.

Explore the Data

The Tapestri Platform can be used to analyze a variety of genetic alterations at single-cell resolution. The following data illustrate the powerful ability of Tapestri to assess lentiviral transduction as well as on-/off-target editing, multiplexed edits, zygosity, and translocations resulting from gene-editing.


click to zoom
Tapestri was used to quantify the percentage of control samples with 0, 25, 50, 75, and 100% lentivirally-transduced cells (N=5 for each). The graph shows linearity between the expected and observed transduction percentages and high precision among replicates.

On/off-target Editing

click to zoom
In a gene-editing project with Agilent Technologies, three genes (HBB, CLTA and RAB11A) were co-edited using CRISPR/Cas9 in a cancer cell line. Tapestri analysis detected on- and predicted off-target editing (as % indels) for each target gene.


click to zoom
In a gene-editing project with Agilent Technologies, three genes (HBB, CLTA and RAB11A) were co-edited using CRISPR/Cas9 in a cancer cell line. Tapestri analysis detected translocation events with high sensitivity (0.2-1.8% of cells).

Multiplexed Edits & Zygosity

click to zoom
Tapestri was used to analyze a CRISPR multiplex editing experiment in which 3 loci were targeted simultaneously in PBMCs. Tapestri resolved the percentage of alleles edited, zygosity, and mutation co-occurrence in all 27 possible combinations.

Get Started

Contact us to discuss your project:

Featured Resources